All Eyes on Tarsus Pharmaceuticals!
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a clinical-stage pharmaceutical company targeting ophthalmic conditions with large unmet medical needs, recently announced that the pivotal Phase 2b/3 Saturn-1 trial which is evaluating TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis has met all pre-specified primary and...
